EMA's human medicines committee (CHMP) has approved a scale-up of the active substance production process at
This recommendation is expected to have significant impact on the supply of Spikevax, the COVID-19 vaccine developed by
EMA's decision reaffirms that the two recently approved US facilities,
Since the granting of a conditional marketing authorisation for Spikevax, the CHMP authorised a total of four manufacturing sites for the production of active substance for this vaccine, two in the US as mentioned above, and two in Visp,
This recommendation does not require a
Contact:
Tel: +31 (0)88 781 8427
Email: press@ema.europa.eu
(C) 2021 Electronic News Publishing, source